Lumito partners in national research collaboration – strengthening the company's position in advanced tissue analysis

Lumito has become a new partner in "Biobarriers – Health, Disorders and Healing", a government-funded project focusing on the development of new technologies to improve health, as well as diagnostics and treatments. This research and collaboration initiative focuses on the body's biological barriers, such as skin and mucous membranes in, for example, the gastrointestinal tract. The partnership strengthens Lumito's position in advanced tissue imaging and opens new opportunities for continued technology development and commercial growth.

Biobarriers is funded by the Knowledge Foundation (KK-stiftelsen), which supports applied research with clear commercial potential. Led by Malmö University, the project brings together leading actors from both academia and industry. For Lumito, the collaboration offers a unique opportunity to contribute to the diagnostics and treatments of the future, while simultaneously strengthening the company's commercial opportunities and networks.

Lumito will contribute its expertise in digital tissue imaging and biomarker quantification, while also benefitting from access to relevant research environments, strategic collaborations and opportunities to further develop its technology in market-relevant applications.

> "Lumito has a unique technology that our researchers need to identify individual cells in tissues. Understanding how these cells affect the health of biological barriers is crucial – not only for our research, but also for the companies involved in the project. The Biobarriers consortium looks forward to an exciting and fruitful collaboration with Lumito," says Johan Engblom, Professor and Project Leader at Malmö University.

> "We are pleased to be accepted as a partner in the Biobarriers project. It gives us the opportunity to contribute with our technology to the project's goals and to collaborate closely with researchers and industry partners. Through this partnership, we can jointly develop new solutions to improve health and drug development, which is fully in line with our strategy to build relevance and create long-term value within advanced tissue imaging," says Sanna Wallenborg, CEO of Lumito.

Lumito has already contributed to the project through its ongoing collaboration with Professor Håkan Eriksson and doctoral researcher Sylwia Hasterok at Malmö University, work which has already been communicated earlier this year through results and presentations.

The project runs from 2019 to 2028 and brings together an extensive network of researchers and companies within life sciences. Through this partnership, Lumito strengthens its position in establishing SCIZYS as a relevant and in-demand technology in both research and drug development.

Further information about the Biobarriers project can be found on Malmö University's website.

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments
Lumito partners in national research collaboration – strengthening the company's position in advanced tissue analysis